In particular, semiconductor specialist Nvidia is viewed as the engine powering the AI vehicle right now. Demand for its most ...

Eli Lilly & Co. closed $48.10 short of its 52-week high ($972.53), which the company achieved on August 22nd.

Ongoing shortages of popular weight loss and diabetes drugs in the U.S. have spurred fierce competition between established ...

While several factors predict sustained glycemic control, predictors of sustained weight control with tirzepatide appear ...

Amgen said on Tuesday that its drug helped improve daily activities including chewing and swallowing in patients suffering ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 598.51% and ...

Eli Lilly has received approval in Japan for Kisunla (donanemab-azbt) to treat early symptomatic Alzheimer's disease.

Eli Lilly (LLY) stock is trading near its all-time highs, with the shares only about 5% away from the record levels set in ...

Minnesota clinics are starting to receive free or low-cost insulin from Eli Lilly and Sanofi. This comes after the Minnesota ...

Novo Nordisk and Eli Lilly are expected to rule the obesity market for a few more years without much challenge. To ensure they stay there as competition enters, the companies are spending billions in ...

Eli Lilly's Kisunla receives Japanese approval for the treatment of early symptomatic Alzheimer's disease: Indianapolis Wednesday, September 25, 2024, 09:00 Hrs [IST] The Ministry ...

Some counterfeits contain bacteria and have high impurity levels or different chemical structures to FDA-approved medicines.